Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study

At 6 months, patients experienced a 1.1% reduction in A1C levels when treated with a combination of SGLT2 inhibitors and GLP-1 receptor agonists.

• Significant reductions in body mass index (2.1 kg/m) and systolic blood pressure (13 mmHg) were also observed.
• Patients with higher baseline A1C levels (≥8.4%) showed greater improvements in A1C, weight, and quality-of-life scores.
• The most substantial reductions in A1C levels and weight occurred in patients who initiated both medications simultaneously.
• Adding GLP-1ra to an existing SGLT2i treatment also resulted in notable A1C and weight reductions.
• A decrease in systolic blood pressure was noted when SGLT2i was added to patients already on GLP-1ra.
• 34.3% of patients achieved the combined endpoint of A1C levels <7% and weight loss ≥5% without experiencing hypoglycemia.

AI simplified